The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

The unique molecular characteristic of chronic myeloid leukemia (CML), the disease-
causing ABL (9q34) to BCR (22q11) translocation, has provided an invaluable tool for …

Interphase fluorescence in situ hybridization (I-FISH) for the BCR-ABL translocation
performed on peripheral blood (PB) white cells has been suggested as a surrogate for …

Abstract Interferon‐α (IFN‐α) alone or in combination with cytostatic drugs can induce major
and durable cytogenetic responses in about 20 to 25% of chronic myeloid leukemia (CML) …

The accuracy of cytogenetic diagnosis in the management of hematological malignancies
has improved significantly over the past 10 years. Fluorescence in situ hybridization (FISH) …

In order to analyze the efficiency of interphase FISH for the detection and monitoring of Ph+
cells in chronic myelogenous leukemia (CML) under interferon (IFN) treatment, the following …

Fluorescence in situ hybridization (FISH), as a new clinical test, is not presently
standardized. For practical reasons, each laboratory must build its own criteria. In this work …

Today, laboratory geneticists help clinical hematologists diagnose chronic granulocytic
leukemia (CGL) and monitor the response of patients undergoing treatment. The most …

Conventional cytogenetics is considered the gold standard for evaluating CML during
interferon (IFN) treatment. Drawbacks to this approach are the small number of metaphases …

For the great majority of patients with chronic myeloid leukaemia (CML), the Philadelphia
(Ph) chromosome is a specific marker of the malignant clone. The standard method to …